Chlorhexidine
ALIMENTARY TRACT AND METABOLISM
Also known as: chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, chlorohex, chlorohexidine
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Chlorhexidine is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1976. DrugCentral lists 11 molecular targets, including SLC22A1, SLC22A2 and SLC22A3. Recorded indications include Gingivitis and Mouth Infection Prevention.
- Approval status: ofp (first approved 1976 by the FDA).
- Molecular targets: SLC22A1, SLC22A2, SLC22A3 and SLC47A2 (11 listed in DrugCentral).
- Indications: Gingivitis and Mouth Infection Prevention.
- ATC code: A01AB03 (Antiinfectives and antiseptics for local oral treatment).
- Molecular formula: C22H30Cl2N10; molecular weight 505.45 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Gingivitis
- Mouth Infection Prevention
Off-label uses (3)
- Aphthous ulcer of mouth
- Dental Plaque Prevention
- Denture stomatitis
Contraindications (3)
- Front Tooth Fillings
- Open wound
- Periodontitis
Mechanism & targets
Molecular targets (11)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Solute carrier family 22 member 1 | SLC22A1 | unknown | IC50 6.68 |
| Solute carrier family 22 member 2 | SLC22A2 | unknown | IC50 6.40 |
| Solute carrier family 22 member 3 | SLC22A3 | unknown | IC50 6.39 |
| Multidrug and toxin extrusion protein 2 | SLC47A2 | unknown | IC50 6.30 |
| Multidrug and toxin extrusion protein 1 | SLC47A1 | unknown | IC50 6.15 |
| Trypanothione reductase | TPR | unknown | Ki 5.70 |
| CAAX prenyl protease 2 | RCE1 | unknown | AC50 5.24 |
| 72 kDa type IV collagenase | MMP2 | unknown | IC50 5.12 |
| Matrix metalloproteinase-9 | MMP9 | unknown | IC50 5.12 |
| Dual specificity protein kinase CLK2 | CLK2 | unknown | IC50 5.04 |
| Synaptojanin-2 | SYNJ2 | unknown | IC50 5.00 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1976-09-17 | FDA | — | MOLNLYCKE HLTH |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A01AB03 | ALIMENTARY TRACT AND METABOLISM › STOMATOLOGICAL PREPARATIONS › STOMATOLOGICAL PREPARATIONS › Antiinfectives and antiseptics for local oral treatment |
A01AB53 | ALIMENTARY TRACT AND METABOLISM › STOMATOLOGICAL PREPARATIONS › STOMATOLOGICAL PREPARATIONS › Antiinfectives and antiseptics for local oral treatment |
B05CA02 | BLOOD AND BLOOD FORMING ORGANS › BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS › IRRIGATING SOLUTIONS › Antiinfectives |
D08AC02 | DERMATOLOGICALS › ANTISEPTICS AND DISINFECTANTS › ANTISEPTICS AND DISINFECTANTS › Biguanides and amidines |
D08AC52 | DERMATOLOGICALS › ANTISEPTICS AND DISINFECTANTS › ANTISEPTICS AND DISINFECTANTS › Biguanides and amidines |
D09AA12 | DERMATOLOGICALS › MEDICATED DRESSINGS › MEDICATED DRESSINGS › Medicated dressings with antiinfectives |
R02AA05 | RESPIRATORY SYSTEM › THROAT PREPARATIONS › THROAT PREPARATIONS › Antiseptics |
S01AX09 | SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFECTIVES › Other antiinfectives |
S02AA09 | SENSORY ORGANS › OTOLOGICALS › ANTIINFECTIVES › Antiinfectives |
S03AA04 | SENSORY ORGANS › OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS › ANTIINFECTIVES › Antiinfectives |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Folliculitis | 3866.2 |
| Muscle injury | 3453.5 |
| Irritable bowel syndrome | 3406.5 |
| Impaired healing | 3270.7 |
| Sleep disorder due to general medical condition, insomnia type | 2879.4 |
| Lower respiratory tract infection | 2872.5 |
| Blister | 2640.3 |
| Helicobacter infection | 2561.6 |
| Duodenal ulcer perforation | 2506.7 |
| Ill-defined disorder | 2502.2 |
| Stomatitis | 2475.2 |
| Gastrointestinal disorder | 2060.3 |
Chemical structure
| Molecular formula | C22H30Cl2N10 |
|---|---|
| Molecular weight | 505.45 g/mol |
| CAS number | 55-56-1 |
| InChIKey | GHXZTYHSJHQHIJ-UHFFFAOYSA-N |
| PubChem CID | 9552079 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Chlorhexidine used for?
DrugCentral lists the following indications for Chlorhexidine: Gingivitis and Mouth Infection Prevention.
How does Chlorhexidine work?
Its molecular targets in DrugCentral include SLC22A1, SLC22A2, SLC22A3 and SLC47A2.
When was Chlorhexidine first approved?
Chlorhexidine was first approved by the FDA in 1976.
What is the chemical formula of Chlorhexidine?
Chlorhexidine has the molecular formula C22H30Cl2N10 and a molecular weight of 505.45 g/mol.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 597 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1484251 — compound record and bioactivity
- PubChem CID 9552079 — chemical identifiers
- DrugBank DB00878 — drug record
- FDA UNII R4KO0DY52L — substance identity
- DailyMed: FDA labels for Chlorhexidine — current prescribing information (label search)
- UniProt O15245 (SLC22A1) — target protein
- UniProt O15244 (SLC22A2) — target protein
- UniProt O75751 (SLC22A3) — target protein
- UniProt Q86VL8 (SLC47A2) — target protein
- UniProt Q96FL8 (SLC47A1) — target protein
- UniProt P08253 (MMP2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.